Corinne Jenkins
Stock Analyst at Goldman Sachs
(1.79)
# 3,339
Out of 5,115 analysts
62
Total ratings
47.73%
Success rate
-2.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corinne Jenkins
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ROIV Roivant Sciences | Maintains: Buy | $24 → $33 | $22.50 | +46.67% | 7 | Dec 15, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $141 → $157 | $112.27 | +39.84% | 11 | Dec 12, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Neutral | $27 → $30 | $35.69 | -15.94% | 6 | Oct 21, 2025 | |
| GERN Geron | Reinstates: Sell | $1 | $1.40 | -28.57% | 4 | Jul 10, 2025 | |
| TGTX TG Therapeutics | Maintains: Neutral | $20 → $22 | $31.07 | -29.19% | 8 | Nov 5, 2024 | |
| FULC Fulcrum Therapeutics | Upgrades: Buy | $6 → $15 | $12.01 | +24.90% | 2 | May 14, 2024 | |
| ALT Altimmune | Reinstates: Neutral | $13 | $3.98 | +226.63% | 3 | Jan 24, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Sell | $25 → $28 | $38.49 | -27.25% | 7 | Jan 9, 2024 | |
| BTAI BioXcel Therapeutics | Maintains: Neutral | $192 → $64 | $1.71 | +3,642.69% | 6 | Aug 15, 2023 | |
| RAPT RAPT Therapeutics | Maintains: Buy | $216 → $184 | $35.84 | +413.39% | 2 | Mar 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $21 | $3.04 | +590.79% | 2 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $14 | $42.38 | -66.97% | 2 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $160 | $7.21 | +2,119.14% | 2 | Dec 15, 2021 |
Roivant Sciences
Dec 15, 2025
Maintains: Buy
Price Target: $24 → $33
Current: $22.50
Upside: +46.67%
Rhythm Pharmaceuticals
Dec 12, 2025
Maintains: Buy
Price Target: $141 → $157
Current: $112.27
Upside: +39.84%
IDEAYA Biosciences
Oct 21, 2025
Maintains: Neutral
Price Target: $27 → $30
Current: $35.69
Upside: -15.94%
Geron
Jul 10, 2025
Reinstates: Sell
Price Target: $1
Current: $1.40
Upside: -28.57%
TG Therapeutics
Nov 5, 2024
Maintains: Neutral
Price Target: $20 → $22
Current: $31.07
Upside: -29.19%
Fulcrum Therapeutics
May 14, 2024
Upgrades: Buy
Price Target: $6 → $15
Current: $12.01
Upside: +24.90%
Altimmune
Jan 24, 2024
Reinstates: Neutral
Price Target: $13
Current: $3.98
Upside: +226.63%
Harmony Biosciences Holdings
Jan 9, 2024
Maintains: Sell
Price Target: $25 → $28
Current: $38.49
Upside: -27.25%
BioXcel Therapeutics
Aug 15, 2023
Maintains: Neutral
Price Target: $192 → $64
Current: $1.71
Upside: +3,642.69%
RAPT Therapeutics
Mar 15, 2023
Maintains: Buy
Price Target: $216 → $184
Current: $35.84
Upside: +413.39%
Mar 7, 2023
Maintains: Buy
Price Target: $25 → $21
Current: $3.04
Upside: +590.79%
Dec 20, 2022
Maintains: Buy
Price Target: $9 → $14
Current: $42.38
Upside: -66.97%
Dec 15, 2021
Initiates: Neutral
Price Target: $160
Current: $7.21
Upside: +2,119.14%